Travel Vaccines Market

Market Overview:

The global travel vaccines market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.6% during 2024-2032. The introduction of combination vaccines in immunization program, rising demand for needle free techniques, and favorable government initiatives represent some of the key factors driving the market.

Favorable Government Initiatives Augmenting Market Growth

The travel vaccines market has been experiencing continuous growth due to favorable government initiatives. Various governing and non-governing agencies are encouraging the adoption of travel vaccines that currently represent one of the primary drivers of the travel vaccines market. They also provide important travel health updates through various websites to travelers that assist in finding the nearest travel clinic and guide tourists about exact vaccinations as per the travel destination. Moreover, they are conducting awareness programs to increase vaccine coverage across the globe.

Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. The market structure is fragmented with a few international and regional players in the industry. The volume of new entrants is moderate in the travel vaccines industry due to low product differentiation and high capital investments in the industry.

What are Travel Vaccines?

Vaccines refer to biological preparations that protect the human body against severe and potentially deadly diseases. They comprise an agent that is manufactured from the surface protein, toxins, or weakened or killed forms of the disease-causing microorganism. They allow the body to produce antibodies, which act as a shield and protect individuals from viruses. Vaccines are also taken by travelers a few weeks prior to their visit to certain regions or countries. Travel Vaccines are effective in preventing numerous serious diseases, such as hepatitis A, diphtheria, pertussis and tetanus (DPT), yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, and Japanese encephalitis, among individuals.

COVID-19 Impact:

The COVID-19 pandemic outbreak caused a severe problem for the travel vaccines industry and imposed unprecedented challenges on numerous countries. The imposition of stringent movement and travel bans across the globe has hampered the demand for travel vaccines. In addition, there has been a massive decline in travel vaccine supplies on account of the travel restrictions. Due to the global lockdown, many production plants were not operational or temporarily closed and shortage or unavailability of labor was observed around the world. Moreover, the production of travel vaccines was constrained due to the ban on exports of raw materials from one country to another. The drastic drop in passenger air transport due to the COVID-19 pandemic and containment measures hindered the sales of travel vaccines. Besides this, there was a shifting preference toward coronavirus vaccines as compared to travel vaccines across the globe. The pandemic had a huge impact on the tourism industry, as many countries have introduced travel restrictions to prohibit the expansion of viruses. Additionally, people preferred to stay at home rather than visit various countries around the world. However, post-pandemic, governing agencies of various countries have relaxed lockdown restrictions on the travel and tourism industry, which is expected to boost the demand for travel vaccines worldwide in the coming years.   

Travel Vaccines Market Trends:

At present, the increasing prevalence of life-threatening infectious diseases among the masses worldwide represents one of the major factors impelling the growth of the market.  Moreover, the introduction of combination vaccines in immunization programs that offer immunity against various diseases among individuals across the globe is strengthening the growth of the market. Apart from this, the growing utilization of travel vaccines due to the increasing number of international tourist arrivals for various purposes is offering a positive market outlook. In addition to this, governing and non-governing agencies of various countries are encouraging the adoption of travel vaccines by conducting awareness programs, which is contributing to the growth of the market. Besides this, technological advancements, such as needle-free injection technology (NFIT), which eliminates the chances of needle stick injuries and avoids other complications among individuals, is offering lucrative growth opportunities to industry investors. Additionally, there is a rise in the demand for effective and cost-efficient travel vaccines among the masses around the world. This, coupled with the increasing awareness among travelers to protect themselves from numerous diseases, is bolstering the growth of the market. Furthermore, the rising adoption of travel vaccines in various countries where vaccines are mandatory prior to visit the place is supporting the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global travel vaccines market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on composition and disease.

Composition Insights:

• Mono Vaccines
• Combination Vaccines
   

The report has provided a detailed breakup and analysis of the travel vaccines market based on the composition. This includes mono vaccines and combination vaccines. According to the report, combination vaccines represented the largest segment, as they provide protection against more than one disease. These vaccines assist in reducing the number of injections required by the users. In addition to this, the rising adoption of combination vaccines among pediatric population, as infants are more susceptible to various infectious diseases due to their weak immune systems, which is supporting the market growth of the segment.  

Disease Insights:

• Hepatitis A 
• DPT
• Yellow Fever
• Typhoid
• Hepatitis B
• Measles and Mumps
• Rabies
• Meningococcal
• Varicella
• Japanese Encephalitis
• Others
   

A detailed breakup and analysis of the travel vaccines market based on the disease has also been provided in the report. This includes hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others. According to the report, hepatitis A accounted for the largest market share, as it is a viral disease that can be transmitted through direct contact with an infectious person or consumption of contaminated food and water. In line with this, the rising utilization of effective hepatitis A vaccine among the travelers to prevent various diseases, is bolstering the growth of the market.            

Regional Insights:

• Asia Pacific
• North America
• Europe
• Middle East and Africa
• Latin America
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America was the largest market for travel vaccines. Some of the factors driving the North America travel vaccines market included the presence of key market players, rising prevalence of life-threatening infectious diseases among individuals, and the increasing production of vaccines. In addition to this, various manufacturers are introducing superior range of travel vaccines, such as a vaccine against varicella. Besides this, companies having travel vaccine franchises are offering vaccines to treat numerous diseases, such as influenza, meningitis, rabies, tick-borne encephalitis, Haemophilus influenzae B (Hib), polio, diphtheria, tetanus, and pertussis, which is strengthening the market growth in the region.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global travel vaccines market. Some of the companies covered in the report include:

• GlaxoSmithKline Pharmaceuticals Limited
• Sanofi Pasteur
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• ALK-Abelló A/S
• Bavarian Nordic A/S
• Crucell (Subsidiary of Johnson & Johnson)
• CSL Limited
• AstraZeneca PLC
• Altimmune, Inc.
• Abbott Laboratories
• Hoffmann-La Roche, Inc.
   

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the travel vaccines market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global travel vaccines market.
• The study maps the leading, as well as the fastest-growing, regional markets.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the travel vaccines industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.